ArticleInternational journal of surgery (London, England)2026
Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Toward a more robust predictive model in esophageal cancer: methodological considerations for the combined use of immunoscore and pan-immune inflammation value.International journal of surgery (London, England) · 2026Article
- Exploratory analysis of serial pan-immune-inflammation value and its early dynamics during neoadjuvant chemotherapy as a predictor of complete cytoreduction at interval debulking surgery in advanced ovarian cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Immunoscore based on CD3American journal of cancer research · 2026Article
- Association of Preoperative Pan-Immune-Inflammation Value with Adverse Pathology and Oncological Outcomes Following Radical Prostatectomy: A Single-Center Retrospective Study.International journal of medical sciences · 2026Article
- Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of combined tumor immunoscore (IS) and pan-immune inflammation value (PIV) in assessing pathological response and survival following neoadjuvant chemoimmunotherapy (NACI) in locally advanced esophageal squamous cell carcinoma (ESCC).
methodsA retrospective cohort of 226 ESCC patients undergoing NACI followed by surgery was analyzed. Local immune status was assessed via IS calculated from CD3⁺/CD8⁺ T-cell densities on immunohistochemical stained tumor sections. Systemic inflammation was measured by peripheral blood PIV. Patients were stratified by median values. The association of IS, PIV alone, and their combination for major pathological response (TRG 0-1) and overall survival (OS) was evaluated.
resultsThe pathological response rate was significantly higher in the high IS group versus the low IS group (54.3% vs. 38.6%; P = 0.023) and in the low PIV group p versus the high PIV group (67.3% vs. 21.2%; P < 0.001). In the combined model, the low IS + high PIV group (Group D) exhibited the lowest pathological response rate (32.0%) and a significantly increased risk of death compared with the optimal group [high IS + low PIV; Group A; hazard ratios = 2.85; 95% confidence interval (CI): 1.70-4.77; P < 0.001]. The dual-parameter IS + PIV model demonstrated superior discriminatory performance: area under the curve (AUC) = 0.78 (95% CI: 0.73-0.84) for discriminating pathological response and AUC = 0.82 (95% CI: 0.75-0.88) for predicting 36-month OS, significantly outperforming single parameters and clinical staging.
conclusionThe IS + PIV dual-parameter model, by integrating local immune activity and systemic inflammatory status, accurately identifies NACI beneficiaries (high IS + low PIV) and high-risk patients (low IS + high PIV), providing an efficient prognostic tool for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.